HB 1397

  • Maryland House Bill
  • 2022 Regular Session
  • Introduced in House
  • Passed House Mar 21, 2022
  • Passed Senate Apr 06, 2022
  • Signed by Governor May 16, 2022

Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance (Insulin Cost Reduction Act)

Abstract

Bill Sponsors (31)

Votes


Actions


May 16, 2022

Office of the Governor

Approved by the Governor - Chapter 405

Apr 07, 2022

House

Returned Passed

Apr 06, 2022

Senate

Third Reading Passed

Apr 05, 2022

Senate

Second Reading Passed

Senate

Favorable Adopted

Apr 04, 2022

Senate

Favorable Report by Finance

Mar 21, 2022

Senate

Referred Finance

House

Third Reading Passed

Mar 18, 2022

House

Second Reading Passed with Amendments

House

Favorable with Amendments {

House

Favorable with Amendments Report by Health and Government Operations

Mar 03, 2022

House

Hearing 3/15 at 1:30 p.m.

House

Rereferred to Health and Government Operations

Feb 17, 2022

House

First Reading House Rules and Executive Nominations

Bill Text

Bill Text Versions Format
First - Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance (Insulin Cost Reduction Act) PDF
Third - Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance (Insulin Cost Reduction Act) PDF
Chapter - Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance (Insulin Cost Reduction Act) PDF

Related Documents

Document Format
Fiscal and Policy Note (Revised) PDF

Sources

Data on Open States is updated periodically throughout the day from the official website of the Maryland General Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.